Agilon Health AGL Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss at other companies
Other financials
Where this comes from
Reported directly by Agilon Health in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss.
The official record: Agilon Health’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agilon Health's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agilon Health's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
- Agilon Health (AGL) reported debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss of $91.07M in Q1 2026.
- How has Agilon Health's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss changed year-over-year?
- Agilon Health's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss decreased by 60.3% year-over-year, from $229.67M to $91.07M.
- What is the long-term trend for Agilon Health's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
- Over 3 years (2022 to 2025), Agilon Health's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss has grown at a -35.8% compound annual growth rate (CAGR), from $417.46M to $110.61M.